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Immunosuppressi ve Activity of the Serum in Patients with 
Brain Tumors and Various Neurological Disorders 
一－Anti-SheepRed Blood Cell Plaque-Forming 
Cell Response in Mouse Spleens 
KAZUO IWAKI 
Department of Neurosurgery, Kyoto University Medical School 
(Director: Prof. Dr目 HAJIMEHANDA) 
The immunosuppressive activity of the serum in patients with brain tumors and various 
neurological disorders was studied by means of anti-sheep red blood cel plaque-forming cel 
response in CaH/He mouse spleens. The samples of serum were obtained from 30 cases with 
glioblastoma, 30 cases with meningioma, 14 cases with other brain tumors, 30 cases with non-
neoplastic diseases and 26 healthy adults. 
A significantly higher frequency of immunosuppression was observed in glioblastomas (26 
of 30), meningiomas (26 of 30), other brain tumors (10 of 14) and non-neoplastic diseases (23 of 
30), as compared to healthy adults (2 of 26). 
The immunosuppressive activity of the serum had no correlation with other immunological 
parameters, including PPD skin tests and gamma globulin levels, except the fact that patients 
with glioblastoma had a higher incidence of negative PPD skin test (80%). 
On the other hand‘the serum immunosuppressive activity in patients with brain tumors 
was found to be positively correlated to the size of lesions measured on the computerized tomo・
graphy, suggesting that the serum immunosuppressive activity was derived from the area of 
cerebral tissue damage or from the secondary reactive process. 
Although the immunosuppressive activity of the serum in healthy adults was extremely weak 
Key words: Sheep red blood cel, Plaque-forming cel, Immunosuppressive factors, Immunoenhancing factors. 
Suppresor cel. 
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when a dose of 0.4 ml was injected, it became stronger when a smaller dose of 0.04 ml was injected. 
In contrast, the serum from patients with brain tumors and other neurological disorders showed 
a decreased immunosuppressive activity when a smaller dose of 0.04 ml was injected. When 0.4 
ml of the serum from patients with brain tumors was injected admixed with 0.4 ml of healthy 
serum, the immunosuppressive activity was neutralized. These results suggest that there exist 
both immunosuppressive and immunoenhancing factors in the healthy serum in competitive 
fashion, and that the immunoenhancing factor is selectively reduced in cases with brain tumors, 
resulting in immunosuppression. It is conceivable that the immunosuppressive factor has its 
optimal concentration in order to express its suppressive activity m relation to the immunoen-
hancing factor. 
Because it was not always successful to transfer the immunosuppressive activity by intra-
peritoneal injection of spleen cells, the activity seems to be mediated by a mechanism other than 






の見られることが報告3,5, 6,17, 18, 40）されている． 免疫
機能示全現象成立の要因には細胞性あるいは種々の体

























2. ヒツジ赤血球（SheepRed Blood Cel: SRBC) 
ヒツジ赤血球（SheepRed Blood Cel: ~REC) の抗
原性，あるいは免疫原性において系統差あるいは固体








量の SRBC浮遊液と 40（、 2時間混合放置し，吸収処
置を行った後，－20°Cに保存，補休として1ヶ月以
内IC使用した．
4, マウスの感作方法及び抗 SRBC.IgM Plaque-
Forming Cell (PFC)算定方法
SRBC 108を静注（IV）投与し， Ig¥1.anti-SRBC. 
PFC産生の peak時である4日自の牌臓を摘出した．
鉄を用いて細切し，メッシュ，綿花，ロートを用いて





浮遊液 50μI, 50% SRBC浮遊液（2000rpm遠沈後の











































2例， craniopharyngioma2例， hemangioblastoma1 































glioblastoma群（平均 1.37g/dl), meni 
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Glioblastoma Manmg1oma Other Non neoplastic He副thy
Neoplastoc Ooseases Control 
01四回目
• No S1gnif icant Suppression 
o S1gnif1cant Suppression P < 0.05 ・SignificantSuppression P < O.O 1 
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Relationship between Immunosuppressive Activity of Serum and Immunological Dynamics. 
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SIZE OF TUMOR 
A. Size of tumor expressed es product of 
the ratios of maximum plane diameters 
of cranial cavity and ma則mumplane 
diameters of t凶nor.
Fig. 3. Correlations between Size of Tumor and Immunosuppressive Activity of Serum. 
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SIZE OF TUMOR 
B. Same as (A ) . except size of tumor 














































0.04 0.4 0.004 ml 
SERUM 
0.04 0.4 
x No Significant Suppression 
。SignificantSuppression P .-:0. 05 
• Significant Suppression P < 0. 01 




















Table 1. Examination of Transfer of PFC-Suppressive Activity by Spleen Cells 
A. Examination of Transfer of PFC-Suppressive Activity by Spleen Cells from 

























0.4 ml I 0.04 ml 
10• 107 I 106 101 
B. Examination of Transfer of PFC-Suppressive Activity by Spleen Cells from 
Healthy, Glioblastoma, Meningioma Serum Injected Mice 
Direct Serum IV I 
1 Exp. Group : 
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* Cell transfer group refers to mice having previously recieved cells from serum injected donors. 




















Table 2. Reduction of Suppressive Activity in Mixture of Healthy and Affected Serums 
Exp. ; Healthy Serum ' A百ectedSerum 
No. 0.4ml 0.4ml 
Healthy Serum 0.4 ml 
＋ 
Affected Serum 0.4 ml 
1 106% 
99% 2 



















































回竺｜ ! 92% 
亡ゴ Sigm五cantSuppression 
いる．腫湯lζ特異的免疫抑制作用を持つ血清因子とし
て blockingfactor16, 20, 27, soJや inhibitionfactorなど
があり，腫湯と関連するものとしては tumorassociat-









10, 11, 12）の immunoregulatoryalpha globulin (IRA）あ















ciated antigenおよび normalbrain antigenが全身の
































phase protein （α1-acid glycoprotein，αi-antitrypsin, ha・ 











































Table 3. Physical Characteristics of Serum Immunosuppressive Factors from Healthy 
and Affected Persons. (Reported Cases) 
凶 ity 1 … l白i aI 戸a 
（ー） ) stable (boiling water 
for lOmin) 
condition or factor 
IRA (NHS) 










alcoholic liver cirrhosis 
chronic histoplasmosis 













（ー） I stable (boiling water 
: for lOmin) 
I stable (56°C, 30 min) 




（ー） i stable (56°C, 30min) 
（ー） ; unstable (55。C,30min) 
[ unstable (56。C,30min) 
I stable (56。C,30min) 
stable (56。C,30min) 
stable (56°C, 30 min) 
stable (56°C, 30 min) 
（ー） ) stable （貯6。C,30min 
（＋） 
( +) I thermostable 
（一）
805 




I Occhino (1973) 
P陀 albumin-p。st I Glasgow (1971) 






associated with α2M 
i u, /3, a2M 




ulatory y-globulin LRG) 
similar to IRA-peptide 
































IRA：・ immunoregulatorya-globulin. NHS: normal human serum. NIP: normal immunosuppressive 
protein. LDL-ln: low density lipoprotein inhibitor. SLE: systemic lupus erythematosus. FDPs：五－
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